Human genetic evidence enriched for side effects of approved drugs
PLOS Genetics · 31.03.2025 · 21 (3) · e1011638
DOI: 10.1371/journal.pgen.1011638 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 31.03.2025. Verfasst von Eric Vallabh Minikel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deerfield Management Company, L.P., Genscience, LLC.
Abstract (Originalsprache)
Safety failures are an important factor in low drug development success rates. Human genetic evidence can select drug targets causal in disease and enrich for successful programs. Here, we sought to determine whether human genetic evidence can also enrich for labeled side effects (SEs) of approved drugs. We combined the SIDER database of SEs with human genetic evidence from genome-wide association studies, Mendelian disease, and somatic mutations. SEs were 2.0 times more likely to occur for drugs whose target possessed human genetic evidence for a trait similar to the SE. Enrichment was highest when the trait and SE were most similar to each other, and was robust to removing drugs where the approved indication was also similar to the SE. The enrichment of genetic evidence was greatest for SEs that were more drug specific, affected more people, and were more severe. There was significant heterogeneity among disease areas the SEs mapped to, with the highest positive predictive value for cardiovascular SEs. This supports the integration of human genetic evidence early in the drug discovery process to identify potential SE risks to be monitored or mitigated in the course of drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, United States of America.
- Deerfield Management Company, L.P, New York City, New York, United States of America.
- Genscience LLC, New York City, New York, United States of America.
ORCID-Profile: Eric Vallabh Minikel, Matthew R Nelson
Förderung
- Deerfield Management Company, L.P.
- Genscience, LLC
Zitieren
APA
Minikel, E. V., & Nelson, M. R. (2025). Human genetic evidence enriched for side effects of approved drugs. PLOS Genetics, 21(3), e1011638. https://doi.org/10.1371/journal.pgen.1011638
Vancouver
Minikel EV, Nelson MR. Human genetic evidence enriched for side effects of approved drugs. PLOS Genetics. 2025;21(3):e1011638. doi:10.1371/journal.pgen.1011638
BibTeX
@article{Minikel2025,
author = {Minikel, Eric Vallabh and Nelson, Matthew R},
title = {Human genetic evidence enriched for side effects of approved drugs},
journal = {PLOS Genetics},
year = {2025},
volume = {21},
number = {3},
pages = {e1011638},
doi = {10.1371/journal.pgen.1011638}
}
EUVIMED